|
Prolonged jaundice following percutaneous coronary
intervention and ticlopidine therapy
PT Tsui, ST Lai, WS Leung, NS Mok, CW Wu, ST Lau, YC Choi
Department of Medicine and Geriatrics, Princess Margaret Hospital,
2-10 Princess Margaret Hospital Road, Laichikok, Hong Kong
Ticlopidine, an adenosine diphosphate receptor blocker,
is widely used to prevent subacute stent thrombosis after percutaneous
coronary intervention. Along with neutropenia and thrombotic thrombocytopenic
purpura, cholestatic hepatitis is one of the most serious potential
side-effects of ticlopidine therapy. Four patients with prolonged
jaundice after ticlopidine therapy, including one fatal case, are
presented. Alternative antithrombotic therapy for subsequent percutaneous
coronary intervention is also described. Clopidogrel therapy was
found to be safe and effective in two patients with a history of
ticlopidine-related cholestatic hepatitis.
Hong Kong Med J 2002;8:57-9
Key words: Angioplasty; Cholestasis; Jaundice; Liver/pathology;
Ticlopidine/adverse effects
|
